Identifying prognostic biomarkers for neuroblastoma using machine learning frameworks

Neuroblastoma is the most common solid tumor in infants, accounting for almost 15% of all childhood cancer-related deaths. Despite decades of progression in surgery, chemotherapy and stem cell therapy, survival in high-risk patients remains below 60%. Current biomarkers – etc. mycn Amplification or alk Mutations – Limited reach exists only in a subset of patients or requires complex testing. These limitations leave a significant gap in effectively predicting disease progression and guided treatment. These challenges need to uncover new interpretable biomarkers that can improve early risk stratification and advance more personalized treatments.

Researchers at Jeong Gin Medical University Children's Hospital have announced a powerful machine learning framework for identifying prognostic biomarkers in neuroblastoma. Public (doi: 10.1002/pdi3.70009) in Pediatric discovery In May 2025, the study will leverage bulk and single-cell RNA sequencing data from over 1,200 patients to build a comprehensive prognostic network. The team's integrated approach not only isolated 11 important gene signatures, but also revealed how these genes interact with tumor microenvironment and drug responses.

To decipher the complex genetic architecture of neuroblastoma, researchers applied an enhanced version of the STSVM machine learning model to analyze bulk RNA-Seq data from 1,207 patients. During this process, 528 genes were discovered that were strongly associated with survival outcomes. Using weighted gene coexpression network analysis (WGCNA), the team filtered this list into 11 hub genes.Oca, BLM, BRCA1, BRCA2, CCNA2, Chek1, E2F1, mad2l1, plk1, rad51and in particular RFC3. High expression of RFC3 Correlates with poor prognosis and hyponormal killer (NK) cell activity, suggesting its role in immune evasion. The study also revealed that the tumor was elevated. RFC3 Expression was more sensitive to vincristine and cyclophosphamide (standard chemotherapeutic agent). Further investigation using single cell RNA sequencing confirmed higher RFC3 Epithelial and bone marrow cells expression in short stories with reduced T cell invasion. These multilayered findings do not only highlight RFC3 It suggests that as a new biomarker it may shape the immune landscape and drug response of neuroblastoma. By combining gene networks, immune signatures, and drug susceptibility profiles, this study provides a rich system-level understanding of disease.

Our integrative approach provides a more complete picture of neuroblastoma biology. identification RFC3 New prognostic markers are particularly promising and therefore not only correlate with patient survival but also with response to major chemotherapy. By integrating machine learning with multi-omic data, we discovered patterns that traditional analyses often overlook. These findings help clinicians better identify high-risk patients, coordinate treatment more effectively, and ultimately improve outcomes in children facing this devastating illness. ”

Senior Research Investigator Dr. Yupeng Cun

This study lays the important foundation for advancing precision drugs in pediatric oncology. Ability to identify prognostic biomarkers RFC3– and link them to both immune profiles and drug reactivity. It can change the diagnosis and treatment of neuroblastoma. It can be used by clinicians in the future RFC3 Expression levels that stratify patients, predict treatment response, and guide individualized care. Furthermore, this integrated pipeline of research could be adapted to other aggressive cancers and could be a valuable tool beyond neuroblastoma. Continuous experimental validation and incorporation of additional OMICS data are key to transforming these insights into clinical applications that improve the survival and quality of life of young patients.